Yongli Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yongli Zhang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Huaguo Liang
Department of Cell Biology and Medical Genetics, School of Basic Medical Sciences Guangdong Pharmaceutical University Guangzhou China
5 shared publicationsPeng Wei
School of Base Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, China
3 shared publicationsWentao Xiao
Department of Gynecology Longgang District Maternity and Child Healthcare Hospital of Shenzhen City (Longgang Maternity and Child Institute of Shantou University Medical College) Shenzhen China
2 shared publicationsZexin Chen
Department of Cell Biology and Medical Genetics, School of Basic Medical Sciences Guangdong Pharmaceutical University Guangzhou China
2 shared publicationsAli Chen
The Experiment Centre, School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, P. R. China
1 shared publicationChangtao Zheng
School of Base Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 29 September 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 18 (1) , 1-14
Research on the process and molecular mechanism of inhibiting serous ovarian cancer by PRTN3 and its inhibitor Sivelestat
Serous ovarian cancer (SOC) is one of the most important diseases affecting women’s health in the world. It is highly occult and often detected in late stage due to the lack of specific molecular markers. Whole exon sequencing was performed on 38 serous ovarian cancer samples, and the mutated gene PRTN3 was selected by bioinformatics analysis. In vitro experiments with serous ovarian cancer cell lines SKOV3 and OVCAR8 and normal ovarian epithelial cell line IOSE80 were performed to verify the expression of PRTN3 and the effect of its inhibitor sivelestat. Xenotransplantation models in vivo also confirmed the effect of sivelestat. We found that Missense Mutation accounted for the vast majority of somatic mutations, and 263 candidate mutant genes were obtained from the mutation frequency, among which three hub gene clusters centered on SF3A2, MUC3A, and PRTN3 were identified, and PRTN3 had the strongest effect on the overall survival of the patients. Subsequently, we verified the expression of PRTN3 in serous ovarian cancer samples and cell lines, PRTN3 was highly expressed in serous ovarian cancer samples and cell lines, and sivelestat could inhibit the migration ability of serous ovarian cancer cell lines. SKOV3 cells were used to construct xenografted tumor models to explore the prospect of PRTN3 as a molecular therapeutic target for ovarian cancer and the application potential of sivelestat, which can inhibit the progression of xenografted tumors in vivo with certain safety. Whole exome sequencing and bioinformatics analysis identified PRTN3 as a potential molecular marker of serous ovarian cancer, and PRTN3 could significantly affect the prognosis of SOC patients. As an inhibitor of PRTN3, sivelestat can inhibit the expression of PRTN3 in SOC cell lines and reduce their migration ability in vitro. In vivo experiments showed that sivelestat can inhibit the growth of subcutaneous transplanted tumor in nude mice with certain safety.
- 29 September 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 18 (1) , 1-14
Open AccessResearch on the process and molecular mechanism of inhibiting serous ovarian cancer by PRTN3 and its inhibitor Sivelestat
Serous ovarian cancer (SOC) is one of the most important diseases affecting women’s health in the world. It is highly occult and often detected in late stage due to the lack of specific molecular markers. Whole exon sequencing was performed on 38 serous ovarian cancer samples, and the mutated gene PRTN3 was selected by bioinformatics analysis. In vitro experiments with serous ovarian cancer cell lines SKOV3 and OVCAR8 and normal ovarian epithelial cell line IOSE80 were performed to verify the expression of PRTN3 and the effect of its inhibitor sivelestat. Xenotransplantation models in vivo also confirmed the effect of sivelestat. We found that Missense Mutation accounted for the vast majority of somatic mutations, and 263 candidate mutant genes were obtained from the mutation frequency, among which three hub gene clusters centered on SF3A2, MUC3A, and PRTN3 were identified, and PRTN3 had the strongest effect on the overall survival of the patients. Subsequently, we verified the expression of PRTN3 in serous ovarian cancer samples and cell lines, PRTN3 was highly expressed in serous ovarian cancer samples and cell lines, and sivelestat could inhibit the migration ability of serous ovarian cancer cell lines. SKOV3 cells were used to construct xenografted tumor models to explore the prospect of PRTN3 as a molecular therapeutic target for ovarian cancer and the application potential of sivelestat, which can inhibit the progression of xenografted tumors in vivo with certain safety. Whole exome sequencing and bioinformatics analysis identified PRTN3 as a potential molecular marker of serous ovarian cancer, and PRTN3 could significantly affect the prognosis of SOC patients. As an inhibitor of PRTN3, sivelestat can inhibit the expression of PRTN3 in SOC cell lines and reduce their migration ability in vitro. In vivo experiments showed that sivelestat can inhibit the growth of subcutaneous transplanted tumor in nude mice with certain safety.
- Open Access
- 11 July 2025
- Published by Scilight Press Pty Ltd in Health and Metabolism
- Vol. 2 (3)
Comparative Study on Metabolic Regulation of SAP Deletion in Normal Mice and Atherosclerotic Mice
SAP is a serum protein associated with an increased risk of cardiovascular events, and researches have shown a significant positive correlation between SAP and the pathogenesis of atherosclerosis. Our previous research found that SAP deficiency in ApoE-/- mice significantly reduced the formation of foam cells and the expression of pro-inflammatory factors, and caused significant metabolic changes. However, it is still unclear whether SAP deficiency has the same function and metabolic regulation effect on normal background mice. In this study, C57 and SAP-/- mice were used as models. Histopathological examinations were performed to evaluate the histomorphological changes of heart, liver, spleen, lung and kidney tissues in SAP-/- mice. The results showed that there were no significant histopathology changes in the main organs of SAP-/- mice, but there were significant differences in the serum metabolic profiles between C57 and SAP-/- mice. It was found that the deficiency of SAP in both C57 and ApoE-/- mice lead to an upregulation of choline, but the regulatory trends on LDL/VLDL were different. Acetate and pyruvate were regulated by SAP deficiency in ApoE-/- mice, but not in C57 mice. In addition, the deletion of SAP also caused significant changes in formate, tyrosine, glycine, glucose, TMAO, taurine, citrate, succinate, and histidine in C57 context, which were not found in the atherosclerosis background. In summary, this study indicates that the metabolic regulation of the SAP gene is not only related to the gene itself, but also related to the physiological or pathological state of the organism.
- 11 July 2025
- Published by Scilight Press Pty Ltd in Health and Metabolism
- Vol. 2 (3)
Open AccessComparative Study on Metabolic Regulation of SAP Deletion in Normal Mice and Atherosclerotic Mice
SAP is a serum protein associated with an increased risk of cardiovascular events, and researches have shown a significant positive correlation between SAP and the pathogenesis of atherosclerosis. Our previous research found that SAP deficiency in ApoE-/- mice significantly reduced the formation of foam cells and the expression of pro-inflammatory factors, and caused significant metabolic changes. However, it is still unclear whether SAP deficiency has the same function and metabolic regulation effect on normal background mice. In this study, C57 and SAP-/- mice were used as models. Histopathological examinations were performed to evaluate the histomorphological changes of heart, liver, spleen, lung and kidney tissues in SAP-/- mice. The results showed that there were no significant histopathology changes in the main organs of SAP-/- mice, but there were significant differences in the serum metabolic profiles between C57 and SAP-/- mice. It was found that the deficiency of SAP in both C57 and ApoE-/- mice lead to an upregulation of choline, but the regulatory trends on LDL/VLDL were different. Acetate and pyruvate were regulated by SAP deficiency in ApoE-/- mice, but not in C57 mice. In addition, the deletion of SAP also caused significant changes in formate, tyrosine, glycine, glucose, TMAO, taurine, citrate, succinate, and histidine in C57 context, which were not found in the atherosclerosis background. In summary, this study indicates that the metabolic regulation of the SAP gene is not only related to the gene itself, but also related to the physiological or pathological state of the organism.
- Open Access
- 31 July 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (21) , 3259-3270
Chromosome instability region analysis and identification of the driver genes of the epithelial ovarian cancer cell lines A2780 and SKOV3
Epithelial ovarian cancer (EOC) is one of the most prevalent gynaecological cancers worldwide. The molecular mechanisms of serous ovarian cancer (SOC) remain unclear and not well understood. SOC cases are primarily diagnosed at the late stage, resulting in a poor prognosis. Advances in molecular biology techniques allow us to obtain a better understanding of precise molecular mechanisms and to identify the chromosome instability region and key driver genes in the carcinogenesis and progression of SOC. Whole‐exome sequencing was performed on the normal ovarian cell line IOSE80 and the EOC cell lines SKOV3 and A2780. The single‐nucleotide variation burden, distribution, frequency and signature followed the known ovarian mutation profiles, without chromosomal bias. Recurrently mutated ovarian cancer driver genes, including LRP1B, KMT2A, ARID1A, KMT2C and ATRX were also found in two cell lines. The genome distribution of copy number alterations was found by copy number variation (CNV) analysis, including amplification of 17q12 and 4p16.1 and deletion of 10q23.33. The CNVs of MED1, GRB7 and MIEN1 located at 17q12 were found to be correlated with the overall survival of SOC patients (MED1: p = 0.028, GRB7: p = 0.0048, MIEN1: p = 0.0051), and the expression of the three driver genes in the ovarian cell line IOSE80 and EOC cell lines SKOV3 and A2780 was confirmed by western blot and cell immunohistochemistry.
- 31 July 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (21) , 3259-3270
Open AccessChromosome instability region analysis and identification of the driver genes of the epithelial ovarian cancer cell lines A2780 and SKOV3
Epithelial ovarian cancer (EOC) is one of the most prevalent gynaecological cancers worldwide. The molecular mechanisms of serous ovarian cancer (SOC) remain unclear and not well understood. SOC cases are primarily diagnosed at the late stage, resulting in a poor prognosis. Advances in molecular biology techniques allow us to obtain a better understanding of precise molecular mechanisms and to identify the chromosome instability region and key driver genes in the carcinogenesis and progression of SOC. Whole‐exome sequencing was performed on the normal ovarian cell line IOSE80 and the EOC cell lines SKOV3 and A2780. The single‐nucleotide variation burden, distribution, frequency and signature followed the known ovarian mutation profiles, without chromosomal bias. Recurrently mutated ovarian cancer driver genes, including LRP1B, KMT2A, ARID1A, KMT2C and ATRX were also found in two cell lines. The genome distribution of copy number alterations was found by copy number variation (CNV) analysis, including amplification of 17q12 and 4p16.1 and deletion of 10q23.33. The CNVs of MED1, GRB7 and MIEN1 located at 17q12 were found to be correlated with the overall survival of SOC patients (MED1: p = 0.028, GRB7: p = 0.0048, MIEN1: p = 0.0051), and the expression of the three driver genes in the ovarian cell line IOSE80 and EOC cell lines SKOV3 and A2780 was confirmed by western blot and cell immunohistochemistry.
- Open Access
- 8 July 2023
- Published by Elsevier in Pharmacological Research
- Vol. 194, 106849
Methyl gallate: Review of pharmacological activity
- 8 July 2023
- Published by Elsevier in Pharmacological Research
- Vol. 194, 106849
Open AccessMethyl gallate: Review of pharmacological activity
- Open Access
- 6 April 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-13
Whole-exome mutational landscape and molecular marker study in mucinous and clear cell ovarian cancer cell lines 3AO and ES2
Background: Ovarian cancer is one of the most lethal cancers in women because it is often diagnosed at an advanced stage. The molecular markers investigated thus far have been unsatisfactory. Methods: We performed whole-exome sequencing on the human ovarian cancer cell lines 3AO and ES2 and the normal ovarian epithelial cell line IOSE-80. Molecular markers of ovarian cancer were screened from shared mutation genes and copy number variation genes in the 6q21-qter region. Results: We found that missense mutations were the most common mutations in the gene (93%). The MUC12, FLG and MUC16 genes were highly mutated in 3AO and ES2 cells. Copy number amplification occurred mainly in 4p16.1 and 11q14.3, and copy number deletions occurred in 4q34.3 and 18p11.21. A total of 23 hub genes were screened, of which 16 were closely related to the survival of ovarian cancer patients. The three genes CCDC170, THBS2 and COL14A1 are most significantly correlated with the survival and prognosis of ovarian cancer. In particular, the overall survival of ovarian cancer patients with high CCDC170 gene expression was significantly prolonged (P < 0.001). The expression of CCDC170 in normal tissues was significantly higher than that in ovarian cancer tissues (P < 0.05), and its expression was significantly decreased in advanced ovarian cancer. Western blotting and immunofluorescence assays also showed that the expression of CCDC170 in ovarian cancer cells was significantly lower than that in normal cells (P < 0.001, P < 0.01). Conclusions: CCDC170 is expected to become a new diagnostic molecular target and prognostic indicator for ovarian cancer patients, which can provide new ideas for the design of antitumor drugs.
- 6 April 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-13
Open AccessWhole-exome mutational landscape and molecular marker study in mucinous and clear cell ovarian cancer cell lines 3AO and ES2
Background: Ovarian cancer is one of the most lethal cancers in women because it is often diagnosed at an advanced stage. The molecular markers investigated thus far have been unsatisfactory. Methods: We performed whole-exome sequencing on the human ovarian cancer cell lines 3AO and ES2 and the normal ovarian epithelial cell line IOSE-80. Molecular markers of ovarian cancer were screened from shared mutation genes and copy number variation genes in the 6q21-qter region. Results: We found that missense mutations were the most common mutations in the gene (93%). The MUC12, FLG and MUC16 genes were highly mutated in 3AO and ES2 cells. Copy number amplification occurred mainly in 4p16.1 and 11q14.3, and copy number deletions occurred in 4q34.3 and 18p11.21. A total of 23 hub genes were screened, of which 16 were closely related to the survival of ovarian cancer patients. The three genes CCDC170, THBS2 and COL14A1 are most significantly correlated with the survival and prognosis of ovarian cancer. In particular, the overall survival of ovarian cancer patients with high CCDC170 gene expression was significantly prolonged (P < 0.001). The expression of CCDC170 in normal tissues was significantly higher than that in ovarian cancer tissues (P < 0.05), and its expression was significantly decreased in advanced ovarian cancer. Western blotting and immunofluorescence assays also showed that the expression of CCDC170 in ovarian cancer cells was significantly lower than that in normal cells (P < 0.001, P < 0.01). Conclusions: CCDC170 is expected to become a new diagnostic molecular target and prognostic indicator for ovarian cancer patients, which can provide new ideas for the design of antitumor drugs.
- 6 March 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 214, 114711
An integrated metabonomics study to reveal the inhibitory effect and metabolism regulation of taurine on breast cancer
- 6 March 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 214, 114711
An integrated metabonomics study to reveal the inhibitory effect and metabolism regulation of taurine on breast cancer
- 1 January 2022
- Published by SAGE Publications in Pharmacognosy Magazine
- Vol. 18 (77) , 216-225
Synthesis, characterization, and anti-hepatocellular carcinoma effect of glycyrrhizin-coupled bovine serum albumin-loaded luteolin nanoparticles
Background: Luteolin (Lut) is a natural flavonoid with low water solubility. Many studies have revealed that its antitumor effect is more understandable. Objectives: Synthesis of glycyrrhizin-coupled bovine serum albumin-loaded Lut nanoparticles (GL-BSA-Lut-Nps) to progress the water solubility, anticancer effect, liver targeting, cycle arrest, induction apoptosis, and regulating the metabolism of Lut. Materials and Methods: The activity screening of GL-BSA-Lut-Nps on Hepatocellular Carcinoma Bel-7402 cells was spotted by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, cell cycle, and apoptosis were measured by flow cytometry. The solubility of GL-BSA-Lut-Nps was evaluated by ultraviolet spectrophotometer. Fluorescein isothiocyanate was employed to label the drug, and the fluorescence intensity of cells after drug uptake was detected under a fluorescence microscope to sense the targeting of GL-BSA-Lut-Nps to tumor cells. The differences of metabolites between Bel-7402 cells treated with GL-BSA-Lut-Nps and the control group were considered by 1 hydrogen-nuclear magnetic resonance metabolomics. Results: The results presented that the GL-BSA-Lut-Nps prepared by solvent removal method had good anti-tumor activity and water solubility in vitro and the No. 4 Lut nanoparticles (GL-BSA-Lut-Nps-4) screened by the MTT method had the best effect. The IC50 of the GL-BSA-Lut-Nps-4 on the Bel-7402 cell inhibition test was 1.999 ± 0.880 mg/mL. The results of cell cycle and apoptosis displayed that the anticancer effect of the prescription is more palpable. The results of the fluorescence original method are proposed to confirm that the experimentally created GL-BSA-Lut-Nps-4 have a liver targeting effect. The study of metabolomics further clarified the metabolic regulation effect of GL-BSA-Lut-Nps-4 on Bel-7402 cells. Conclusion: It delivers a theoretical basis for the development of new high-efficiency and low-toxicity traditional Chinese medicine preparations for liver cancer.
- 1 January 2022
- Published by SAGE Publications in Pharmacognosy Magazine
- Vol. 18 (77) , 216-225
Synthesis, characterization, and anti-hepatocellular carcinoma effect of glycyrrhizin-coupled bovine serum albumin-loaded luteolin nanoparticles
Background: Luteolin (Lut) is a natural flavonoid with low water solubility. Many studies have revealed that its antitumor effect is more understandable. Objectives: Synthesis of glycyrrhizin-coupled bovine serum albumin-loaded Lut nanoparticles (GL-BSA-Lut-Nps) to progress the water solubility, anticancer effect, liver targeting, cycle arrest, induction apoptosis, and regulating the metabolism of Lut. Materials and Methods: The activity screening of GL-BSA-Lut-Nps on Hepatocellular Carcinoma Bel-7402 cells was spotted by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, cell cycle, and apoptosis were measured by flow cytometry. The solubility of GL-BSA-Lut-Nps was evaluated by ultraviolet spectrophotometer. Fluorescein isothiocyanate was employed to label the drug, and the fluorescence intensity of cells after drug uptake was detected under a fluorescence microscope to sense the targeting of GL-BSA-Lut-Nps to tumor cells. The differences of metabolites between Bel-7402 cells treated with GL-BSA-Lut-Nps and the control group were considered by 1 hydrogen-nuclear magnetic resonance metabolomics. Results: The results presented that the GL-BSA-Lut-Nps prepared by solvent removal method had good anti-tumor activity and water solubility in vitro and the No. 4 Lut nanoparticles (GL-BSA-Lut-Nps-4) screened by the MTT method had the best effect. The IC50 of the GL-BSA-Lut-Nps-4 on the Bel-7402 cell inhibition test was 1.999 ± 0.880 mg/mL. The results of cell cycle and apoptosis displayed that the anticancer effect of the prescription is more palpable. The results of the fluorescence original method are proposed to confirm that the experimentally created GL-BSA-Lut-Nps-4 have a liver targeting effect. The study of metabolomics further clarified the metabolic regulation effect of GL-BSA-Lut-Nps-4 on Bel-7402 cells. Conclusion: It delivers a theoretical basis for the development of new high-efficiency and low-toxicity traditional Chinese medicine preparations for liver cancer.